Heparan sulfate on tumor cell surfaces inhibited lytic anticancer peptide activity, identifying a tumor resistance mechanism and suggesting heparanase combination therapy to unmask cancer cells for peptide killing.
Key findingHeparan sulfate on tumor cell surfaces inhibited lytic anticancer peptide activity, identifying a tumor resistance mechanism and suggesting heparanase
What the researchers found
Heparan sulfate on tumor cell surfaces inhibited lytic anticancer peptide activity, identifying a tumor resistance mechanism and suggesting heparanase combination therapy to unmask cancer cells for peptide killing.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2009.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells.
BMC cancer, 9, 183
Citation
Fadnes, Bodil; Rekdal, Oystein; Uhlin-Hansen, Lars. (2009). The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells.. BMC cancer, 9, 183. https://doi.org/10.1186/1471-2407-9-183